RADNET, Inc. (NASDAQ:RDNT) Files An 8-K Results of Operations and Financial ConditionItem 2.02
On August 9, 2018 RadNet, Inc. (“RadNet”) issued a press release and held a conference call regarding our financial results for the quarter ended June 30, 2018. A copy of the press release is furnished as Exhibit 99.1 and a copy of the transcript of the conference call is furnished as Exhibit 99.2 to this Current Report.
The information in this Current Report, including Exhibit 99.1 and Exhibit 99.2 is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934 or otherwise subject to the liabilities of that Section. The information in this Current Report, including Exhibit 99.1 and Exhibit 99.2 shall not be incorporated by reference into any registration statement or other document filed with the Commission.
|Item 9.01||FINANCIAL STATEMENTS AND EXHIBITS.|
RadNet, Inc. ExhibitEX-99.1 2 radnet_8k-ex9901.htm PRESS RELEASE Exhibit 99.1 FOR IMMEDIATE RELEASE RadNet Reports Second Quarter Financial Results to Include Record Revenue and Reaffirms Guidance Ranges ·Total Net Revenue increased 6.3% to $244.4 million in the second quarter of 2018 from $230.0 million in the second quarter of 2017 ·Adjusted EBITDA(1) increased 3.0% to $38.2 million in the second quarter of 2018 from $37.0 million in the second quarter of 2017 ·Earnings Per Share was $0.11 in the second quarter of 2018,…To view the full exhibit click
About RADNET, Inc. (NASDAQ:RDNT)
RadNet, Inc. is a provider of freestanding, fixed-site outpatient diagnostic imaging services in the United States. The Company operates directly or indirectly through joint ventures with hospitals, approximately 300 centers located in California, Delaware, Florida, Maryland, New Jersey, New York and Rhode Island. Its centers provide physicians with imaging capabilities to facilitate the diagnosis and treatment of diseases and disorders. Its services include magnetic resonance imaging (MRI), computed tomography (CT), positron emission tomography (PET), nuclear medicine, ultrasound, diagnostic radiology (X-ray), fluoroscopy and other related procedures. It operates approximately 140 fixed-site, freestanding outpatient diagnostic imaging facilities in California, over 10 in Delaware, three in Florida, 50 in Maryland, 20 in New Jersey, 20 in the Rochester and Hudson Valley areas of New York, approximately 40 in New York City, as well as five in Rhode Island.